Cargando…

Spironolactone use is associated with improved outcomes in heart failure with mid‐range ejection fraction

AIMS: Spironolactone has been shown to improve outcomes in patients with heart failure (HF) with reduced ejection fraction (EF). We investigated whether the discharge use of spironolactone could be associated with better long‐term outcomes among patients with HF with mid‐range EF (HFmrEF). METHODS A...

Descripción completa

Detalles Bibliográficos
Autores principales:	Enzan, Nobuyuki, Matsushima, Shouji, Ide, Tomomi, Kaku, Hidetaka, Higo, Taiki, Tsuchihashi‐Makaya, Miyuki, Tsutsui, Hiroyuki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7083406/ https://www.ncbi.nlm.nih.gov/pubmed/31951680 http://dx.doi.org/10.1002/ehf2.12571

Ejemplares similares

Electrocardiographic Left Ventricular Hypertrophy Is Independently Associated With Better Long-Term Outcomes in Dilated Cardiomyopathy Patients
por: Matsushima, Shouji, et al.
Publicado: (2019)

Beneficial Effects of Dipeptidyl Peptidase-4 Inhibitors on Heart Failure With Preserved Ejection Fraction and Diabetes
por: Enzan, Nobuyuki, et al.
Publicado: (2023)

Long-Term Outcomes of Heart Failure Patients With Preserved, Mildly Reduced, and Reduced Ejection Fraction
por: Nagata, Takuya, et al.
Publicado: (2023)

Clinical Characteristics and Contemporary Management of Patients With Cardiomyopathies in Japan　― Report From a National Registry of Clinical Personal Records ―
por: Enzan, Nobuyuki, et al.
Publicado: (2021)

Sex Differences in Time-Dependent Changes in B-Type Natriuretic Peptide in Hypertrophic Cardiomyopathy
por: Enzan, Nobuyuki, et al.
Publicado: (2021)

Beta‐Blocker Use Is Associated With Prevention of Left Ventricular Remodeling in Recovered Dilated Cardiomyopathy
por: Enzan, Nobuyuki, et al.
Publicado: (2021)

The use of angiotensin II receptor blocker is associated with greater recovery of cardiac function than angiotensin‐converting enzyme inhibitor in dilated cardiomyopathy
por: Enzan, Nobuyuki, et al.
Publicado: (2022)

Machine learning‐based model for predicting 1 year mortality of hospitalized patients with heart failure
por: Tohyama, Takeshi, et al.
Publicado: (2021)

Propensity-Matched Study of Early Cardiac Rehabilitation in Patients With Acute Decompensated Heart Failure
por: Enzan, Nobuyuki, et al.
Publicado: (2023)

Left Ventricular Noncompaction with Multiple Thrombi in Apical Aneurysm
por: Yakabe, Daisuke, et al.
Publicado: (2019)

Efficacy and safety of spironolactone in the heart failure with mid-range ejection fraction and heart failure with preserved ejection fraction: A meta-analysis of randomized clinical trials
por: Xiang, Yajie, et al.
Publicado: (2019)

Regression of Electrocardiographic Left Ventricular Hypertrophy and Strain Pattern Using Pharmacotherapy in a Patient With Dilated Cardiomyopathy
por: Hashimoto, Toru, et al.
Publicado: (2020)

Blockade of L-type Ca(2+) channel attenuates doxorubicin-induced cardiomyopathy via suppression of CaMKII-NF-κB pathway
por: Ikeda, Soichiro, et al.
Publicado: (2019)

Outcomes of Spironolactone Withdrawal in Dilated Cardiomyopathy With Improved Ejection Fraction
por: Chen, Yanjia, et al.
Publicado: (2021)

Heart Failure with Mid-Range Ejection Fraction - State of the Art
por: Mesquita, Evandro Tinoco, et al.
Publicado: (2019)

Heart rate in heart failure with mid-range ejection fraction
por: Yılmaz, Mehmet Birhan
Publicado: (2019)

Heart failure with mid-range or mildly reduced ejection fraction
por: Savarese, Gianluigi, et al.
Publicado: (2021)

Phenotypes of heart failure with preserved ejection fraction and effect of spironolactone treatment
por: Choy, Manting, et al.
Publicado: (2022)

IFN-γ-STAT1-ERK Pathway Mediates Protective Effects of Invariant Natural Killer T Cells Against Doxorubicin-Induced Cardiomyocyte Death
por: Sada, Masashi, et al.
Publicado: (2023)

Treatment of Heart Failure with Mid-Range Ejection Fraction: What Is the Evidence
por: Koufou, Eleni-Evangelia, et al.
Publicado: (2021)

Pulmonary Hypertension in Patients With Heart Failure With Mid-Range Ejection Fraction
por: Maeder, Micha T., et al.
Publicado: (2021)

Iron Overload via Heme Degradation in the Endoplasmic Reticulum Triggers Ferroptosis in Myocardial Ischemia-Reperfusion Injury
por: Miyamoto, Hiroko Deguchi, et al.
Publicado: (2022)

Epicardial fat in heart failure patients with mid‐range and preserved ejection fraction
por: van Woerden, Gijs, et al.
Publicado: (2018)

Heart Failure With Mid-range or Recovered Ejection Fraction: Differential Determinants of Transition
por: Margonato, Davide, et al.
Publicado: (2020)

Dilated Cardiomyopathy With Mid‐Range Ejection Fraction at Diagnosis: Characterization and Natural History
por: Gentile, Piero, et al.
Publicado: (2019)

Targeting efficacy of spironolactone in patients with heart failure with preserved ejection fraction: the TOPCAT study
por: Zhou, Hui‐min, et al.
Publicado: (2022)

Heart failure with mid‐range ejection fraction: characterization of patients from the PINNACLE Registry®
por: Ibrahim, Nasrien E., et al.
Publicado: (2019)

The impact of heart rate on patients diagnosed with heart failure with mid-range ejection fraction
por: Xin, Yanguo, et al.
Publicado: (2019)

Central and Obstructive Apneas in Heart Failure With Reduced, Mid-Range and Preserved Ejection Fraction
por: Borrelli, Chiara, et al.
Publicado: (2019)

Rehospitalization burden and morbidity risk in patients with heart failure with mid‐range ejection fraction
por: Santas, Enrique, et al.
Publicado: (2020)

Heart Failure With Mid-range Ejection Fraction: Every Coin Has Two Sides
por: Zhu, Kaiyuan, et al.
Publicado: (2021)

Treatment of Heart Failure With Mid-Range Ejection Fraction: A Summary of Current Evidence
por: Ma, Teng, et al.
Publicado: (2021)

Epicardial Adipose Tissue and Outcome in Heart Failure With Mid-Range and Preserved Ejection Fraction
por: van Woerden, Gijs, et al.
Publicado: (2021)

Spironolactone Use and Improved Outcomes in Patients With Heart Failure With Preserved Ejection Fraction With Resistant Hypertension
por: Tsujimoto, Tetsuro, et al.
Publicado: (2020)

A composite metric for predicting benefit from spironolactone in heart failure with preserved ejection fraction
por: Belkin, Mark N., et al.
Publicado: (2021)

Rationale and Study Design of the Withdrawal of Spironolactone for Heart Failure with Improved Left Ventricular Ejection Fraction
por: Hyun, Junho, et al.
Publicado: (2021)

Effusive–constrictive pericarditis secondary to pneumopericardium associated with gastropericardial fistula
por: Ono, Yoshiyasu, et al.
Publicado: (2020)

ZBP1 Protects Against mtDNA-Induced Myocardial Inflammation in Failing Hearts
por: Enzan, Nobuyuki, et al.
Publicado: (2023)

Clinical characteristics of hospitalized heart failure patients with preserved, mid‐range, and reduced ejection fractions in Japan
por: Shiga, Tsuyoshi, et al.
Publicado: (2019)

Changes in the Left Ventricular Ejection Fraction and Outcomes in Hospitalized Heart Failure Patients with Mid-range Ejection Fraction: A Prospective Observational Study
por: Tsukamoto, Kei, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_35bp09j4bf49mi28jtbni4nask